2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-142050
    (R)-IDHP 950665-05-1 98%
    (R)-IDHP is an isomer of IDHP, a salvia metabolite that exerts vasorelaxant effects by inhibiting Ca2+ release and Ca2+ inward flow in voltage-dependent and receptor-operated calcium channels in vascular smooth muscle cells. IDHP is used in studies of cardiovascular disease.
    (R)-IDHP
  • HY-14252A
    Milrinone lactate 100286-97-3 98%
    Milrinone lactate is a potent inotropic dilating agent. Milrinone lactate shows simultaneous positive inotropic and vasodilating activities. Milrinone lactate promotes reduction of SVR and PVR in patients with DCM and NYHA class III and IV of heart failure. Milrinone lactate has the potential for the research of cardiovascular function after cardiac surgery and in septic shock.
    Milrinone lactate
  • HY-14252S
    Milrinone-d3 2749393-50-6 98%
    Milrinone-d3 is deuterium labeled Milrinone. Milrinone is a PDE3 inhibitor, and also an inotrope and vasodilator.
    Milrinone-d3
  • HY-142620
    TRPV4 antagonist 3 2681273-35-6 98%
    TRPV4 antagonist 3 is a TRPV4 antagonist (pIC50 = 8.4).
    TRPV4 antagonist 3
  • HY-142691
    DCN1-UBC12-IN-1 2374827-31-1 98%
    DCN1-UBC12-IN-1 is potent and selective DCN1-UBC12 inhibitor with an IC50 of 2.86 nM. Anticardiac fibrotic effect.
    DCN1-UBC12-IN-1
  • HY-142692
    DCN1-UBC12-IN-3 2374827-45-7 98%
    DCN1-UBC12-IN-3 is potent and selective DCN1-UBC12 inhibitor with an IC50 of 2.25 nM. Anticardiac fibrotic effect.
    DCN1-UBC12-IN-3
  • HY-142694
    DCN1-UBC12-IN-2 2374827-47-9 98%
    DCN1-UBC12-IN-2 is a potent and specific DCN1-UBC12 inhibitor (IC50=9.55 nM). DCN1-UBC12-IN-2 could specifically target DCN1-UBC12 interaction and relieve Ang II-induced cardiac fibroblast activation.
    DCN1-UBC12-IN-2
  • HY-142697
    SGC agonist 1 1426309-31-0 98%
    SGC agonist 1 is a potent agonist of soluble guanylate cyclase (SGC). SGC agonist 1 improves solubility combined with high cell permeability. SGC agonist 1 has the potential for the research of cardiovascular disease (extracted from patent WO2016030354A1, compound 18A).
    SGC agonist 1
  • HY-142698
    SGC agonist 2 2735713-77-4 98%
    SGC agonist 2 is a potent agonist of soluble guanylate cyclase (SGC). Soluble guanylate cyclase is a key signal transduction enzyme in the NO-sGC-cGMP signaling pathway. SGC agonist 2 has the potential for the research of cardiovascular disease (heart failure, pulmonary hypertension, angina, myocardial infarction) and fibrotic diseases (renal fibrosis, systemic sclerosis) (extracted from patent WO2021219088A1, compound 031).
    SGC agonist 2
  • HY-14284S
    Nilvadipine-d4 98%
    Nilvadipine-d4 is deuterium labeled Nilvadipine. Nilvadipine is a potent calcium channel antagonist, and the IC50 value is around 0.1 nM.
    Nilvadipine-d4
  • HY-142972
    19(S)-HETE 115461-40-0 98%
    19(S)-HETE is an arachidonic acid metabolite produced by cytochrome P450 enzymes. 19(S)-HETE is a full orthosteric agonist of the prostacyclin (IP) receptor with an EC50 value of 567 nM. 19(S)-HETE inhibits platelet activation and relaxation of vessels.
    19(S)-HETE
  • HY-14299D
    Indacaterol acetate 1000160-96-2 98%
    Indacaterol acetate is an orally active ultra-long-acting β2 adrenergic receptor (ADRB2) agonist. Indacaterol acetate inhibits NF-κB activity in a β-arrestin2-dependent manner, preventing further lung damage and improving lung function in COPD (chronic obstructive pulmonary disorder). Indacaterol acetate can also be used in cardiovascular disease research.
    Indacaterol acetate
  • HY-143243
    Antioxidant agent-5 2684291-60-7 98%
    Antioxidant agent-5 (compound D-6) is a potent antioxidant agent. Antioxidant agent-5 can inhibit oxLDL (oxidized low-density lipoprotein)-induced apoptosis and the expression of ICAM-1 and VCAM-1 in VECs. Antioxidant agent-5 suppresses oxLDL-induced increase of ROS level and nuclear translocation of NF-κB. Antioxidant agent-5 protects against oxLDL-induced endothelial injury by activating Nrf2/HO-1 anti-oxidation pathway.
    Antioxidant agent-5
  • HY-143289
    NTPDase-IN-3 2883147-45-1 98%
    NTPDase-IN-3 (Compound 5e) is a NTPDase inhibitor, with IC50 values of: 0.38 μM (NTPDase3), 0.05 μM (NTPDase8), 0.21 μM (NTPDase1), and 1.07 μM (NTPDase2). NTPDase-IN-3 can be used in the research of cancers and thrombosis.
    NTPDase-IN-3
  • HY-143294
    sEH inhibitor-2 2816102-69-7 98%
    sEH inhibitor-2 (compound 5l) is an orally active (predicted percentage absorption: 71.2-88.4%) soluble epoxide hydrolase (sEH) inhibitor, with an IC50 of 0.9 nM. sEH inhibitor-2 can maintain epoxyeicosatrienoic acids (EETs) serum level in high concentrations. sEH inhibitor-2 can be used in study of cardiovascular protection.
    sEH inhibitor-2
  • HY-143300
    BRD4-BD1-IN-2 2761321-26-8 98%
    BRD4-BD1-IN-2 is a selective BRD4-BD1 inhibitor, with an IC50 of 2.51 µM (20-times greater than that of BD2). BRD4-BD1-IN-2 can be used in studies of cancer and cardiovascular diseases.
    BRD4-BD1-IN-2
  • HY-143313
    Protease-Activated Receptor-1 antagonist 1 98%
    Protease-Activated Receptor-1 antagonist 1 (Compound 13) is a protease-activated receptor-1 (PAR-1) antagonist with the IC50 of 3 nM by FLIPR technology. Protease-Activated Receptor-1 antagonist 1 can be used for the research of thrombotic cardiovascular, myocardial infarction, and peripheral arterial disease.
    Protease-Activated Receptor-1 antagonist 1
  • HY-143314
    Protease-Activated Receptor-1 antagonist 2 1454588-34-1 98%
    Protease-Activated Receptor-1 antagonist 2 is an orally active protease-activated receptor-1 (PAR-1) antagonist, with an IC50 value of 7 nM. Protease-Activated Receptor-1 antagonist 2 has favorable pharmacokinetic properties which is useful in the research of cardiovascular disease (CVD), such as atherosclerosis and restenosis.
    Protease-Activated Receptor-1 antagonist 2
  • HY-143315
    Protease-Activated Receptor-1 antagonist 3 98%
    Protease-Activated Receptor-1 antagonist 3 is a potent protease-activated receptor-1 antagonist with an IC50 value of 7 nM. Protease-Activated Receptor-1 antagonist 3 shows binding affinity for hERG K+ channel with an IC50 value of 9 µM.
    Protease-Activated Receptor-1 antagonist 3
  • HY-143476
    Plasma kallikrein-IN-2 98%
    Plasma kallikrein-IN-2 (Compound 198) is a potent plasma kallikrein (PKal) inhibitor with an IC50 of 0.1 nM. Plasma kallikrein-IN-2 can be used for hereditary angioedema, diabetic macular edema, and diabetic retinopathy research.
    Plasma kallikrein-IN-2
Cat. No. Product Name / Synonyms Application Reactivity